Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of MK-1084 plus pembrolizumab versus placebo plus pembrolizumab as first-line therapy for KRAS G12C-mutant metastatic non-small cell lung cancer with PD-L1 TPS at least 50%
CTR20242278Phase 3Active
- Sponsor
- MSD
- Start
- Nov 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of calderasib, pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by MSD. Started Nov 2024; status: active.
02
Drugs
calderasibpembrolizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20242278.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242278.